{"id":33985,"date":"2020-06-25T11:00:56","date_gmt":"2020-06-25T11:00:56","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=33985"},"modified":"2020-07-06T10:23:36","modified_gmt":"2020-07-06T10:23:36","slug":"bioavailability-and-bioequivalence-of-allopurinol-in-two-tablet-formulations","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol13no2\/bioavailability-and-bioequivalence-of-allopurinol-in-two-tablet-formulations\/","title":{"rendered":"Bioavailability and Bioequivalence of Allopurinol in Two Tablet Formulations"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

Description<\/strong><\/p>\n

The chemical structure of allopurinol is 1, 5-dihydro-4H<\/em>-pyrazolo [3, 4-d<\/em>] pyrimidin-4-one. It is a xanthine oxidase inhibitor that\u2019s administered orally and intravenously. It may be a white undefined mass with an atomic weight of 158.09 and atomic formula C5<\/sub>H3<\/sub>N4<\/sub>NaO.\u00a0 It has the structural formula below. The pKa of allopurino sodium is 9.31 (Maddison etal.2009).<\/p>\n

Allopurinol respond on purine catabolism,\u00a0without\u00a0disrupting the biosynthesis of purines. It decreases the generation of uric acid by representing the biochemical responses quickly going before its formation.2<\/sup><\/p>\n

Allopurinol could be an auxiliary simple of the characteristics purine base, hypoxanthine. Allopurinol is an inhibitor of xanthine oxidase,<\/em>3,4<\/sup> the protein capable for the change\u00a0 of hypoxanthine to xanthine and of xanthine to uric acid, the end output of purine metabolism in man. Allopurinol is metabolized to the corresponding xanthine analogue, oxipurinol (alloxanthine), which also is an inhibitor of xanthine oxidase.<\/em>4,5<\/sup> Therefore, this enzyme is the target\u00a0of medicine\u00a0in opposition to\u00a0gout and hyperuricemia.<\/p>\n

Therefore, it is an isomer of hypoxanthine and inhibits the\u00a0manufacturing\u00a0of uric acid, the metabolite answerable for\u00a0gout,\u00a0by\u00a0inhibiting enzyme xanthine oxidase. Allopurinol is used to\u00a0deal with chronic gout (gouty arthritis) and gout is a\u00a0sort of\u00a0acute arthritis\u00a0that is\u00a0prompted\u00a0by\u00a0hyperuricemia and results inside the\u00a0crystallization of sodium urate.<\/em>6<\/sup> This\u00a0condition\u00a0is\u00a0resulting from\u00a0as\u00a0well\u00a0much\u00a0uric acid\u00a0within the blood. This\u00a0medication\u00a0works\u00a0by means of\u00a0causing\u00a0much less\u00a0uric acid to be manufactured\u00a0by means of the body.<\/em>7 <\/sup>Allopurinol will\u00a0now not\u00a0lessen\u00a0a gout offense that has as of now begun.\u00a0 Also, it does\u00a0now not cure\u00a0gout,\u00a0but\u00a0it’s going to\u00a0help\u00a0save you\u00a0gout attacks. Be that as it may, it were after you\u2019ve got been taking it frequently for many months.\u00a0 Allopurinol will prevent gout attacks.<\/em>8,9<\/sup><\/p>\n

Allopurinol include\u00a0certain\u00a0forms of\u00a0kidney stones or\u00a0different\u00a0kidney issues. Certain\u00a0medicines\u00a0or therapeutic drug treatments\u00a0can\u00a0appreciably\u00a0increase\u00a0the quantity\u00a0of uric acid\u00a0within the\u00a0body. This can motive gout or kidney troubles\u00a0in\u00a0some\u00a0people.10<\/sup> Allopurinol\u00a0is also\u00a0used to\u00a0prevent\u00a0these\u00a0issues, and can be given as either a\u00a0pill\u00a0or an injection if necessary.<\/p>\n

For allopurinol, the following\u00a0must\u00a0be considered; Allergy. A\u00a0percentage\u00a0of\u00a0humans\u00a0develop\u00a0a rash and need to\u00a0discontinue\u00a0this drug. The\u00a0maximum\u00a0severe\u00a0adverse\u00a0event\u00a0is a\u00a0hypersensitivity\u00a0syndrome consisting of fever, skin\u00a0rush, eosinophilia, hepatitis,\u00a0and irritating\u00a0renal function.<\/em>1<\/sup>1<\/sup><\/p>\n

In a few\u00a0cases, allopurinol\u00a0allergic reaction\u00a0syndrome pregnancy. In spite of that thinks\u00a0approximately on birth\u00a0abandons have\u00a0now not\u00a0been\u00a0tired\u00a0pregnant women,\u00a0 allopurinol has\u00a0not\u00a0been detailed to purpose problems\u00a0in\u00a0humans. In one\u00a0take a look at\u00a0in mice,\u00a0huge\u00a0sums of allopurinol\u00a0brought on beginning defects and different undesirable\u00a0impacts.<\/em>12,13<\/sup> In any cases, allopurinol did\u00a0no longer motive beginning defects or\u00a0different\u00a0issues\u00a0in rats or rabbits given dosages up\u00a0to twenty instances the sum as rule given to\u00a0humans. Breast-feeding- allopurinol passes into the breast drain. Mothers who’re taking this pharmaceutical and who\u00a0want\u00a0to breast-feed ought to\u00a0observe\u00a0this with their specialist.<\/em>14<\/sup>
\nRecently, an\u00a0excessive\u00a0occurrence\u00a0of gout and hyperuricemia\u00a0related to hyperlipidemia, obesity, and hypertension were\u00a0demonstrated, and these headaches are perceived as a\u00a0hazard\u00a0element\u00a0for inducing mortality and ischemic\u00a0coronary\u00a0heart\u00a0disease.15<\/sup><\/em> It has\u00a0also\u00a0been\u00a0proven\u00a0that hyperuricemia\u00a0will increase the relative\u00a0threat\u00a0of cardiovascular or cerebrovascular diseases,12 <\/sup>and uric acid is\u00a0stated\u00a0to be an independent\u00a0risk\u00a0thing\u00a0inside the remedy\u00a0of hypertension.16<\/sup> Considering\u00a0these\u00a0factors, it has been advocated\u00a0that asymptomatic hyperuricemic\u00a0patients\u00a0should\u00a0receive\u00a0remedy\u00a0for\u00a0reducing\u00a0blood uric acid levels (Qianrui Li etal. 2019).\u00a0 Indeed,\u00a0sufferers\u00a0are\u00a0dealt with\u00a0a uric acid\u00a0manipulate\u00a0drug to\u00a0save you\u00a0recurrence of gout.1<\/sup>6,<\/sup> 18<\/sup><\/p>\n

Materials and Methods<\/strong><\/p>\n

Extraction of Plasma Samples\u00a0\u00a0\u00a0\u00a0 <\/strong><\/p>\n

The blood samples (5ml) were collected from 20 healthy volunteers (age 20-40 years ,body weigh 55-84 Kg, body height 160-174 cm) for each allopurinol formula (Table 1), in different times between (0.5-12) hours after oral administration of 300 mg of allopurinol tablet.\u00a0 Blood samples were taken prior to each administration and at 0 time and post administration at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 9.0 and 12.0 hours after the dose.\u00a0\u00a0 Blood samples were collected in single randomized crossover studies with interval of 7 days between two periods. Plasma were obtained from blood samples to which heparin (25 \u00b5g), were added to 10 ml tube before centrifugation at 900 g.,\u00a0 plasma (0.5\u00a0ml) in ground-glass centrifuge tube, was added to 0.2\u00a0<\/sup>ml of 20% perchloric acid, mixed well, and centrifuged at 850\u00a0<\/sup>g<\/em> for 10\u00a0min at 4\u00b0C. The supernatant was removed and filtered through a 22-\u00b5m Millipore GV13<\/sub> syringe filter. A 20-\u00b5l aliquot of the filtrate was analyzed by HPLC.<\/p>\n

Assay by HPLC<\/strong><\/p>\n

High performance liquid chromatography (HPLC) 10AVP, Shimadzu, Japan, was used to determine the concentration of allopurinol in plasma.\u00a0 Plasma (0.5\u00a0ml) was added to 0.2\u00a0<\/sup>ml of 20% perchloric acid, mixed well, and centrifuged at 850\u00a0<\/sup>g<\/em> for 10\u00a0min at 4\u00b0C. The supernatant was removed and filtered through a 22-\u00b5m Millipore GV13<\/sub> syringe filter.\u00a0 A 20-\u00b5l aliquot of the filtrate was analyzed by using a Shimadzu 10AVP,\u00a0HPLC machine, operating in isocratic mode, equipped with a suplico \u00b5Bondapak C18<\/sub> column (4.6 mm i.d. x 250 mm, 5 \u00b5m particle size), an absorbance detector set at 254\u00a0nm. The mobile phase was 50\u00a0mM KH2<\/sub>PO4<\/sub>, pH 6.0,\u00a0at a flow rate of 1\u00a0ml\/min. Authentic allopurinol standards were run under similar conditions, and these values were used to calculate concentrations of allopurinol in plasma samples.<\/p>\n

Linearity of the Chromatographic Method<\/strong>\u00a0<\/strong><\/p>\n

The typical chromatogram obtained for a standard of allopurinol is shown in Fig. 1. The retention time of allopurinol in chromatogram is about 5.7 min.<\/p>\n\n\n\n
\"Figure<\/td>\nFigure 1: HPLC chromatigrams of allopurinol standard (B) and plasma (A)<\/strong><\/p>\n

Click here to View Figure<\/span><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Precision and Accuracy<\/strong><\/p>\n

HPLC method was evaluated by measuring the chromatographic peak area of allopurinol, 10 times on the same standard (5 mcg\/ml). The coefficient of variation was 1.12 %. Injection precision less than 5% RSD (Relative Standard Deviation) are considered appropriate for these trace level determinations. The accuracy of the method was estimated by injecting five different standard of the same concentration (1 mcg\/ml) obtaining a recovery of 99.6% with an RSD of 1.6%.<\/p>\n

Recovery of the Method<\/strong><\/p>\n

Table 2 show the results obtained in the analysis of the extracts from spiked plasma with different quantities of allopurinol (0.78 mcg. 10.2 mcg and 26.7 mcg); the average recovery was 98.5%.\u00a0\u00a0 The RSD values ranged from 1.6% for a quantity of 10.2 \u03bcg (intra-day) to 5.6% for 0.78 \u03bcg in the inter-day study.<\/p>\n

Statistical Analysis<\/strong><\/p>\n

The pharmacokinetic characteristics of allopurinol were determined from the plasma concentration-time data. Peak plasma concentration (Cmax<\/sub>) and time to maximum plasma concentration (Tmax<\/sub>) were determined directly from raw data. The area under the curve (AUC0-t<\/sub>, from 0 to last measured concentration) was calculated by the trapezoidal method.<\/p>\n

Student\u2019s (t)-test was used to estimate the significance of the variations in the results obtained for the tested formulations.<\/p>\n

Table 1: Characteristics of the volunteers<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Subject<\/strong><\/td>\nSex<\/strong><\/td>\nAge\\years<\/strong><\/td>\nHeight \\cm<\/strong><\/td>\nWeight\\kg.<\/strong><\/td>\n<\/tr>\n
1<\/td>\nM<\/td>\n23<\/td>\n170<\/td>\n68<\/td>\n<\/tr>\n
2<\/td>\nM<\/td>\n24<\/td>\n165<\/td>\n65<\/td>\n<\/tr>\n
3<\/td>\nM<\/td>\n26<\/td>\n173<\/td>\n63<\/td>\n<\/tr>\n
4<\/td>\nM<\/td>\n29<\/td>\n166<\/td>\n70<\/td>\n<\/tr>\n
5<\/td>\nM<\/td>\n20<\/td>\n174<\/td>\n80<\/td>\n<\/tr>\n
6<\/td>\nM<\/td>\n35<\/td>\n172<\/td>\n78<\/td>\n<\/tr>\n
7<\/td>\nM<\/td>\n32<\/td>\n171<\/td>\n74<\/td>\n<\/tr>\n
8<\/td>\nM<\/td>\n27<\/td>\n167<\/td>\n75<\/td>\n<\/tr>\n
9<\/td>\nM<\/td>\n33<\/td>\n169<\/td>\n73<\/td>\n<\/tr>\n
10<\/td>\nM<\/td>\n29<\/td>\n173<\/td>\n84<\/td>\n<\/tr>\n
11<\/td>\nM<\/td>\n30<\/td>\n168<\/td>\n72<\/td>\n<\/tr>\n
12<\/td>\nM<\/td>\n40<\/td>\n174<\/td>\n69<\/td>\n<\/tr>\n
13<\/td>\nF<\/td>\n24<\/td>\n160<\/td>\n58<\/td>\n<\/tr>\n
14<\/td>\nF<\/td>\n23<\/td>\n164<\/td>\n57<\/td>\n<\/tr>\n
15<\/td>\nF<\/td>\n24<\/td>\n166<\/td>\n60<\/td>\n<\/tr>\n
16<\/td>\nF<\/td>\n26<\/td>\n168<\/td>\n55<\/td>\n<\/tr>\n
17<\/td>\nF<\/td>\n29<\/td>\n170<\/td>\n59<\/td>\n<\/tr>\n
18<\/td>\nF<\/td>\n30<\/td>\n161<\/td>\n60<\/td>\n<\/tr>\n
19<\/td>\nF<\/td>\n32<\/td>\n165<\/td>\n58<\/td>\n<\/tr>\n
20<\/td>\nF<\/td>\n34<\/td>\n165<\/td>\n60<\/td>\n<\/tr>\n
Mean<\/td>\n<\/td>\n28.5<\/td>\n168.5<\/td>\n66.90<\/td>\n<\/tr>\n
\u00b1SD<\/td>\n<\/td>\n4.94<\/td>\n4.11<\/td>\n8.59<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong><\/p>\n

Table 2: Intra- and inter-day variation of the method for allopurinol<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Conc. Added<\/strong><\/td>\nIntra-day (n=10)<\/strong><\/td>\nInter-day (n=10)<\/strong><\/td>\n<\/tr>\n
(mcg)<\/td>\nRSD*<\/td>\nError<\/td>\nConc.Found (mcg)<\/td>\nRSD*<\/td>\nError<\/td>\nConc.Found (mcg)<\/td>\n<\/tr>\n
(%)<\/td>\n(%)<\/td>\n(%)<\/td>\n(%)<\/td>\n<\/tr>\n
0.78<\/td>\n4.8<\/td>\n2.6<\/td>\n0.76 +<\/u>0.03<\/td>\n5.6<\/td>\n6.4<\/td>\n0.73 +<\/u> 0.04<\/td>\n<\/tr>\n
10.2<\/td>\n1.6<\/td>\n0.9<\/td>\n10.1 +<\/u>0.12<\/td>\n3.1<\/td>\n2.9<\/td>\n0.91 +<\/u> 0.29<\/td>\n<\/tr>\n
26.7<\/td>\n1.9<\/td>\n1.1<\/td>\n26.4 +<\/u> 0.25<\/td>\n4.2<\/td>\n2.3<\/td>\n26.1 +<\/u> 0.53<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

*Relative Standard Deviation (RSD)<\/p>\n

Results and Discussion<\/strong><\/p>\n

The chromatograms shown in Fig. 1 are the results of standards of allopurinol standard (B) and free plasma (A) which observed that no endogenous interference occurred in the chromatogram, the figures (2, 3) show the chromatogram after oral administration of 300mg allopurinol at selective result of analysis carried out 2 and 6 hours respectively.<\/p>\n

Linear calibration curves of allopurinol peak area versus plasma concentrations were obtained with plasma standards containing 5 \u2013 300 ug\/ml (Fig. 2).\u00a0 The calibration curve constructed during the assays of allopurinol in actual plasma samples of the bioavailability trial were being carried out (19).\u00a0 Correlation coefficient for these linear regression were consistently greater than 0.98.9 (n=5) making one point calibration feasible.<\/p>\n\n\n\n
\"Figure<\/td>\nFigure\u00a02:\u00a0Calibration curves of allopurinol (ug\/ml) standards\u00a0<\/strong><\/p>\n

Click here to View Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Precision and accuracy, Percentage\u00a0intra-assay and inter-day coefficient of variation (CV %) for allopurinol\u00a0were\u00a097.2\u2013100.3,\u00a0within the concentration range 0.5\u20135.0\u00a0\u03bcg\/ml (Table 2). Table2\u00a0display\u00a0the\u00a0effects\u00a0obtained\u00a0within the\u00a0analysis\u00a0of the extracts from spiked plasma with different\u00a0portions\u00a0of allopurinol (0.78\u00a0mcg. 10.2 mcg and 26.7 mcg); the average\u00a0restoration\u00a0turned into\u00a098.5%. The RSD values ranged from 1.6% for a\u00a0quantity\u00a0of 10.2 \u03bcg (intra-day) to\u00a05.6 % for\u00a00.78\u00a0\u03bcg\u00a0within the\u00a0inter-day study.<\/p>\n

Plasma concentrations of allopurinol were measurable for most subjects up to 12 hours following the administration of oral allopurinol tablets (Table 3, 4).<\/p>\n

Table 3: Mean concentration of allopurinol (ug\\ml) in plasma after administration of oral 300 mg Hyporic acid tablet (SDI) to 20 healthy volunteers.<\/strong><\/p>\n

Time – Hours<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
No.<\/strong><\/td>\n0.0<\/strong><\/td>\n0.5<\/strong><\/td>\n1.0<\/strong><\/td>\n1.5<\/strong><\/td>\n2.0<\/strong><\/td>\n3.0<\/strong><\/td>\n4.0<\/strong><\/td>\n6.0<\/strong><\/td>\n9.0<\/strong><\/td>\n12.0<\/strong><\/td>\n<\/tr>\n
1<\/td>\n0<\/td>\n5.6<\/td>\n17.3<\/td>\n32.1<\/td>\n23.4<\/td>\n15.8<\/td>\n10.5<\/td>\n6.6<\/td>\n3.1<\/td>\n1.2<\/td>\n<\/tr>\n
2<\/td>\n0<\/td>\n4.2<\/td>\n15.3<\/td>\n29.6<\/td>\n22.1<\/td>\n14.9<\/td>\n9.3<\/td>\n5.0<\/td>\n2.4<\/td>\n1.1<\/td>\n<\/tr>\n
3<\/td>\n0<\/td>\n3.9<\/td>\n12.4<\/td>\n22.5<\/td>\n15.3<\/td>\n9.7<\/td>\n5.5<\/td>\n3.7<\/td>\n2.1<\/td>\n0.9<\/td>\n<\/tr>\n
4<\/td>\n0<\/td>\n5.4<\/td>\n16.7<\/td>\n26.3<\/td>\n16.4<\/td>\n10.2<\/td>\n6.4<\/td>\n3.0<\/td>\n1.6<\/td>\n0.75<\/td>\n<\/tr>\n
5<\/td>\n0<\/td>\n6.3<\/td>\n16.0<\/td>\n30.1<\/td>\n21.2<\/td>\n13.7<\/td>\n8.3<\/td>\n4.5<\/td>\n2.4<\/td>\n1.1<\/td>\n<\/tr>\n
6<\/td>\n0<\/td>\n3.5<\/td>\n13.1<\/td>\n27.8<\/td>\n18.5<\/td>\n10.4<\/td>\n6.4<\/td>\n3.1<\/td>\n1.7<\/td>\n0.85<\/td>\n<\/tr>\n
7<\/td>\n0<\/td>\n5.1<\/td>\n16.8<\/td>\n32.2<\/td>\n24.3<\/td>\n16.1<\/td>\n10.0<\/td>\n5.7<\/td>\n2.5<\/td>\n1.1<\/td>\n<\/tr>\n
8<\/td>\n0<\/td>\n6.5<\/td>\n17.5<\/td>\n34.5<\/td>\n25.6<\/td>\n17.3<\/td>\n9.8<\/td>\n4.8<\/td>\n2.2<\/td>\n0.9<\/td>\n<\/tr>\n
9<\/td>\n0<\/td>\n4.6<\/td>\n14.3<\/td>\n24.0<\/td>\n16.2<\/td>\n8.9<\/td>\n4.8<\/td>\n2.8<\/td>\n1.8<\/td>\n0.8<\/td>\n<\/tr>\n
10<\/td>\n0<\/td>\n4.8<\/td>\n14.9<\/td>\n28.4<\/td>\n20.0<\/td>\n12.2<\/td>\n6.7<\/td>\n3.9<\/td>\n1.9<\/td>\n0.75<\/td>\n<\/tr>\n
11<\/td>\n0<\/td>\n4.0<\/td>\n15.3<\/td>\n31.6<\/td>\n22.3<\/td>\n15.4<\/td>\n10.2<\/td>\n5.1<\/td>\n2.4<\/td>\n1.0<\/td>\n<\/tr>\n
12<\/td>\n0<\/td>\n5.2<\/td>\n16.7<\/td>\n33.4<\/td>\n25.7<\/td>\n17.9<\/td>\n11.4<\/td>\n5.7<\/td>\n2.7<\/td>\n1.2<\/td>\n<\/tr>\n
13<\/td>\n0<\/td>\n6.4<\/td>\n18.0<\/td>\n35.1<\/td>\n27.2<\/td>\n18.2<\/td>\n12.7<\/td>\n6.0<\/td>\n2.9<\/td>\n1.4<\/td>\n<\/tr>\n
14<\/td>\n0<\/td>\n3.9<\/td>\n14.0<\/td>\n28.2<\/td>\n19.8<\/td>\n11.3<\/td>\n6.6<\/td>\n3.3<\/td>\n1.7<\/td>\n0.8<\/td>\n<\/tr>\n
15<\/td>\n0<\/td>\n5.5<\/td>\n16.2<\/td>\n29.4<\/td>\n20.0<\/td>\n12.0<\/td>\n7.4<\/td>\n4.0<\/td>\n1.9<\/td>\n0.9<\/td>\n<\/tr>\n
16<\/td>\n0<\/td>\n6.5<\/td>\n16.9<\/td>\n33.7<\/td>\n24.6<\/td>\n16.7<\/td>\n10.1<\/td>\n5.3<\/td>\n2.6<\/td>\n1.3<\/td>\n<\/tr>\n
17<\/td>\n0<\/td>\n4.2<\/td>\n14.7<\/td>\n29.0<\/td>\n19.9<\/td>\n11.8<\/td>\n7.2<\/td>\n4.2<\/td>\n2.0<\/td>\n0.95<\/td>\n<\/tr>\n
18<\/td>\n0<\/td>\n3.7<\/td>\n13.2<\/td>\n27.4<\/td>\n18.3<\/td>\n10.3<\/td>\n6.0<\/td>\n3.0<\/td>\n1.4<\/td>\n0.65<\/td>\n<\/tr>\n
19<\/td>\n0<\/td>\n5.3<\/td>\n16.0<\/td>\n32.5<\/td>\n23.6<\/td>\n17.4<\/td>\n9.6<\/td>\n4.6<\/td>\n1.9<\/td>\n0.85<\/td>\n<\/tr>\n
20<\/td>\n0<\/td>\n3.8<\/td>\n14.2<\/td>\n28.5<\/td>\n19.2<\/td>\n11.0<\/td>\n5.9<\/td>\n2.9<\/td>\n1.7<\/td>\n0.75<\/td>\n<\/tr>\n
Mean<\/td>\n0<\/td>\n4.92<\/td>\n15.475<\/td>\n29.815<\/td>\n21.18<\/td>\n13.56<\/td>\n8.24<\/td>\n4.36<\/td>\n2.145<\/td>\n0.963<\/td>\n<\/tr>\n
\u00b1SD<\/td>\n0<\/td>\n1.006<\/td>\n1.591<\/td>\n3.372<\/td>\n3.391<\/td>\n3.105<\/td>\n2.227<\/td>\n1.151<\/td>\n0.464<\/td>\n0.205<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Table 4:\u00a0Mean concentration of allopurinol (ug\\ml) in plasma after administration of oral 300 mg Zyloric tablet (GlaxoWelcome) to 20 healthy volunteers.\u00a0<\/strong><\/p>\n

Time – Hours<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
No.<\/strong><\/td>\n0.0<\/strong><\/td>\n0.5<\/strong><\/td>\n1.0<\/strong><\/td>\n1.5<\/strong><\/td>\n2.0<\/strong><\/td>\n3.0<\/strong><\/td>\n4.0<\/strong><\/td>\n6.0<\/strong><\/td>\n9.0<\/strong><\/td>\n12.0<\/strong><\/td>\n<\/tr>\n
1<\/td>\n0<\/td>\n6.4<\/td>\n18.5<\/td>\n33.2<\/td>\n23.5<\/td>\n16.2<\/td>\n11.3<\/td>\n6.2<\/td>\n3.3<\/td>\n1.32<\/td>\n<\/tr>\n
2<\/td>\n0<\/td>\n5.3<\/td>\n15.4<\/td>\n31.2<\/td>\n21.0<\/td>\n15.3<\/td>\n10.2<\/td>\n5.4<\/td>\n2.9<\/td>\n1.2<\/td>\n<\/tr>\n
3<\/td>\n0<\/td>\n5.2<\/td>\n15.6<\/td>\n32.6<\/td>\n20.5<\/td>\n14.6<\/td>\n9.0<\/td>\n4.5<\/td>\n2.3<\/td>\n1.0<\/td>\n<\/tr>\n
4<\/td>\n0<\/td>\n4.6<\/td>\n15.2<\/td>\n29.8<\/td>\n19.4<\/td>\n13.9<\/td>\n8.9<\/td>\n4.3<\/td>\n2.0<\/td>\n0.9<\/td>\n<\/tr>\n
5<\/td>\n0<\/td>\n3.9<\/td>\n14.3<\/td>\n27.8<\/td>\n18.3<\/td>\n14.2<\/td>\n10.3<\/td>\n6.0<\/td>\n3.0<\/td>\n1.4<\/td>\n<\/tr>\n
6<\/td>\n0<\/td>\n3.7<\/td>\n14.0<\/td>\n26.3<\/td>\n16.7<\/td>\n12.4<\/td>\n7.6<\/td>\n4.0<\/td>\n1.9<\/td>\n0.85<\/td>\n<\/tr>\n
7<\/td>\n0<\/td>\n4.8<\/td>\n14.5<\/td>\n27.0<\/td>\n16.9<\/td>\n12.0<\/td>\n7.5<\/td>\n3.8<\/td>\n1.75<\/td>\n0.75<\/td>\n<\/tr>\n
8<\/td>\n0<\/td>\n4.9<\/td>\n15.6<\/td>\n29.6<\/td>\n20.1<\/td>\n14.3<\/td>\n9.4<\/td>\n4.7<\/td>\n2.1<\/td>\n1.0<\/td>\n<\/tr>\n
9<\/td>\n0<\/td>\n5.8<\/td>\n16.9<\/td>\n32.1<\/td>\n21.5<\/td>\n15.0<\/td>\n10.3<\/td>\n5.9<\/td>\n2.6<\/td>\n1.2<\/td>\n<\/tr>\n
10<\/td>\n0<\/td>\n6.5<\/td>\n18.3<\/td>\n33.9<\/td>\n22.6<\/td>\n17.5<\/td>\n11.8<\/td>\n6.0<\/td>\n3.1<\/td>\n1.4<\/td>\n<\/tr>\n
11<\/td>\n0<\/td>\n6.7<\/td>\n19.2<\/td>\n34.5<\/td>\n24.0<\/td>\n16.5<\/td>\n11.3<\/td>\n5.5<\/td>\n2.7<\/td>\n1.5<\/td>\n<\/tr>\n
12<\/td>\n0<\/td>\n5.3<\/td>\n16.4<\/td>\n33.1<\/td>\n21.7<\/td>\n15.9<\/td>\n10.2<\/td>\n5.2<\/td>\n2.4<\/td>\n1.0<\/td>\n<\/tr>\n
13<\/td>\n0<\/td>\n4.7<\/td>\n15.2<\/td>\n29.8<\/td>\n19.9<\/td>\n14.2<\/td>\n9.7<\/td>\n4.9<\/td>\n2.3<\/td>\n0.9<\/td>\n<\/tr>\n
14<\/td>\n0<\/td>\n4.3<\/td>\n15.3<\/td>\n29.7<\/td>\n18.8<\/td>\n13.9<\/td>\n9.4<\/td>\n4.7<\/td>\n2.2<\/td>\n0.88<\/td>\n<\/tr>\n
15<\/td>\n0<\/td>\n3.9<\/td>\n13.8<\/td>\n26.3<\/td>\n17.4<\/td>\n12.7<\/td>\n8.8<\/td>\n4.3<\/td>\n1.9<\/td>\n0.85<\/td>\n<\/tr>\n
16<\/td>\n0<\/td>\n5.7<\/td>\n16.5<\/td>\n30.2<\/td>\n20.6<\/td>\n14.8<\/td>\n9.2<\/td>\n4.9<\/td>\n1.8<\/td>\n0.8<\/td>\n<\/tr>\n
17<\/td>\n0<\/td>\n5.8<\/td>\n17.0<\/td>\n33.4<\/td>\n24.5<\/td>\n16.3<\/td>\n10.6<\/td>\n5.1<\/td>\n2.3<\/td>\n1.0<\/td>\n<\/tr>\n
18<\/td>\n0<\/td>\n6.9<\/td>\n17.4<\/td>\n31.5<\/td>\n19.7<\/td>\n13.9<\/td>\n8.2<\/td>\n4.0<\/td>\n1.8<\/td>\n0.85<\/td>\n<\/tr>\n
19<\/td>\n0<\/td>\n6.2<\/td>\n16.7<\/td>\n30.7<\/td>\n21.2<\/td>\n15.7<\/td>\n9.6<\/td>\n4.6<\/td>\n1.9<\/td>\n0.80<\/td>\n<\/tr>\n
20<\/td>\n0<\/td>\n4.4<\/td>\n14.3<\/td>\n28.6<\/td>\n18.6<\/td>\n14.2<\/td>\n8.9<\/td>\n4.4<\/td>\n1.75<\/td>\n0.75<\/td>\n<\/tr>\n
Mean<\/td>\n0<\/td>\n5.25<\/td>\n16.005<\/td>\n30.565<\/td>\n20.345<\/td>\n14.675<\/td>\n9.61<\/td>\n4.92<\/td>\n2.3<\/td>\n1.017<\/td>\n<\/tr>\n
\u00b1SD<\/td>\n0<\/td>\n0.977<\/td>\n1.552<\/td>\n2.507<\/td>\n2.237<\/td>\n1.418<\/td>\n1.168<\/td>\n0.724<\/td>\n0.485<\/td>\n0.234<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Allopurinol is given orally and unexpectedly absorbed from the top gastrointestinal tract.\u00a0 Studies have detected allopurinol within the blood 30-60 minutes after dosing. Estimates of bioavailability range from 67% to 90%. (Helmy et.al. 2014, and Rathod et.al. 2017).\u00a0\u00a0 A Peak plasma levels of allopurinol usually arise approximately 1.5 hours after oral administration of Zyloric, however fall swiftly and are barely detectable after 6 hours (Figure 3, 4 and 5).\u00a0 Allopurinol is negligibly bound by way of plasma proteins and thus varieties in protein binding are not thought to be significantly change clearance (Guerra et al. 2001).<\/p>\n\n\n\n
\"Figure<\/a><\/td>\nFigure 3: Mean\u00a0Plasma\u00a0concentration\u00a0of allopurinol (ug\/ml) after oral administration of Hyporic acid\u00a0<\/strong><\/strong><\/p>\n

Click here to View Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
\"Figure<\/td>\nFigure\u00a04:\u00a0Mean\u00a0Plasma\u00a0concentration\u00a0of\u00a0allopurinol (ug\/ml)\u00a0after oral\u00a0administration of\u00a0Zyloric<\/strong><\/p>\n

Click here to View Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
\"Figure<\/td>\nFigure\u00a05: Comparison between Reference drug (Zyloric , Glaxo Wellcome)\u00a0and Test drug (Hyporic, SDI)<\/strong><\/p>\n

Click here to View Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

The self-evidence degree of dispersion of allopurinol is approximately 1.6 litre\/kg body weight which appears moderately sizable uptake by through tissues. Tissue concentrations of allopurinol have not longer been suggested in humans, however it\u2019s possibly that allopurinol and Oxipurinol can be present in the highest concentrations inside the liver and intestinal mucosa in which xanthine oxidase activity is high (Guerra et al. 2001). Approximately 20% of the ingested allopurinol is excreted\u00a0within the\u00a0feces.<\/p>\n

Elimination of allopurinol is\u00a0particularly\u00a0by manner of\u00a0metabolic conversion to oxipurinol with beneficial\u00a0resource\u00a0of xanthine oxidase and aldehyde oxidase,<\/em>3<\/sup>\u00a0with\u00a0much less\u00a0than 10 % of the unchanged drug excreted\u00a0in the\u00a0urine.\u00a0 Oxipurinol is\u00a0a much\u00a0less\u00a0effective\u00a0inhibitor of xanthine oxidase than allopurinol,\u00a0but the\u00a0plasma\u00a0half-life\u00a0of oxipurinol is\u00a0ways more prolonged.<\/em>4\u00a0<\/sup>Estimates variety\u00a0in man ranged between\u00a013\u00a0to 30 hours. Therefore\u00a0powerful\u00a0inhibition of xanthine oxidase is maintained over a 24 hour\u00a0period\u00a0with every day\u00a0dose of allopurinol.<\/p>\n

Patients with\u00a0everyday\u00a0renal\u00a0function\u00a0will gradually\u00a0gather\u00a0oxipurinol\u00a0till\u00a0a steady state\u00a0plasma oxipurinol\u00a0popularity\u00a0is reached (4).\u00a0 Such patients, taking three hundred mg of allopurinol\u00a0in keeping with\u00a0day, will\u00a0typically\u00a0have plasma oxipurinol concentrations of 5-10 mg\/litre (Guerra et al. 2001).
\nAllopurinol has a plasma half lifestyles\u00a0of\u00a0about\u00a01\u00a0to two\u00a0hours, while\u00a0in the present study, it was found that the half-life of Hyporic drug as a test and Zyloric drug as a reference were 2.0 and 2.1 hours, respectively ( Tables 5 and 6).<\/p>\n

Table 5: Pharmacokinetic of allopurinol (ug\\ml) in plasma after administration of oral 300 mg Hyporic acid tablet (SDI) to 20 healthy volunteers.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
No.,<\/strong><\/td>\nKa<\/strong><\/td>\nKa0.5t<\/strong><\/td>\nKelem.<\/strong><\/td>\nKelem.0.5t<\/strong><\/td>\nCmax<\/strong><\/td>\nTmax<\/strong><\/td>\nAUC<\/strong><\/td>\n<\/tr>\n
1<\/td>\n2.256<\/td>\n0.307<\/td>\n0.320<\/td>\n2.169<\/td>\n32.1<\/td>\n1.5<\/td>\n104.2<\/td>\n<\/tr>\n
2<\/td>\n2.586<\/td>\n0.268<\/td>\n0.341<\/td>\n2.032<\/td>\n29.6<\/td>\n1.5<\/td>\n102.8<\/td>\n<\/tr>\n
3<\/td>\n2.314<\/td>\n0.299<\/td>\n0.318<\/td>\n2.176<\/td>\n22.5<\/td>\n1.5<\/td>\n98.6<\/td>\n<\/tr>\n
4<\/td>\n2.258<\/td>\n0.307<\/td>\n0.359<\/td>\n1.928<\/td>\n26.3<\/td>\n1.5<\/td>\n75.4<\/td>\n<\/tr>\n
5<\/td>\n1.864<\/td>\n0.372<\/td>\n0.343<\/td>\n2.022<\/td>\n30.1<\/td>\n1.5<\/td>\n99.7<\/td>\n<\/tr>\n
6<\/td>\n2.640<\/td>\n0.262<\/td>\n0.371<\/td>\n1.867<\/td>\n27.8<\/td>\n1.5<\/td>\n69.74<\/td>\n<\/tr>\n
7<\/td>\n2.385<\/td>\n0.291<\/td>\n0.325<\/td>\n2.134<\/td>\n32.2<\/td>\n1.5<\/td>\n89.86<\/td>\n<\/tr>\n
8<\/td>\n1.981<\/td>\n0.349<\/td>\n0.368<\/td>\n1.882<\/td>\n34.5<\/td>\n1.5<\/td>\n103.61<\/td>\n<\/tr>\n
9<\/td>\n2.269<\/td>\n0.305<\/td>\n0.351<\/td>\n1.974<\/td>\n24.0<\/td>\n1.5<\/td>\n68.53<\/td>\n<\/tr>\n
10<\/td>\n1.173<\/td>\n0.591<\/td>\n0.383<\/td>\n1.810<\/td>\n28.4<\/td>\n1.5<\/td>\n74.62<\/td>\n<\/tr>\n
11<\/td>\n2.684<\/td>\n0.258<\/td>\n0.334<\/td>\n2.072<\/td>\n31.6<\/td>\n1.5<\/td>\n94.325<\/td>\n<\/tr>\n
12<\/td>\n2.334<\/td>\n0.297<\/td>\n0.353<\/td>\n1.964<\/td>\n33.4<\/td>\n1.5<\/td>\n98.42<\/td>\n<\/tr>\n
13<\/td>\n2.069<\/td>\n0.335<\/td>\n0.318<\/td>\n2.176<\/td>\n35.1<\/td>\n1.5<\/td>\n99.61<\/td>\n<\/tr>\n
14<\/td>\n2.557<\/td>\n0.271<\/td>\n0.379<\/td>\n1.830<\/td>\n28.2<\/td>\n1.5<\/td>\n87.520<\/td>\n<\/tr>\n
15<\/td>\n2.161<\/td>\n0.321<\/td>\n0.360<\/td>\n1.926<\/td>\n29.4<\/td>\n1.5<\/td>\n78.38<\/td>\n<\/tr>\n
16<\/td>\n1.911<\/td>\n0.363<\/td>\n0.336<\/td>\n2.061<\/td>\n33.7<\/td>\n1.5<\/td>\n99.35<\/td>\n<\/tr>\n
17<\/td>\n2.506<\/td>\n0.277<\/td>\n0.323<\/td>\n2.148<\/td>\n29.0<\/td>\n1.5<\/td>\n92.46<\/td>\n<\/tr>\n
18<\/td>\n2.544<\/td>\n0.272<\/td>\n0.373<\/td>\n1.856<\/td>\n27.4<\/td>\n1.5<\/td>\n84.512<\/td>\n<\/tr>\n
19<\/td>\n2.210<\/td>\n0.314<\/td>\n0.380<\/td>\n2.248<\/td>\n32.5<\/td>\n1.5<\/td>\n100.310<\/td>\n<\/tr>\n
20<\/td>\n2.637<\/td>\n0.263<\/td>\n0.397<\/td>\n1.745<\/td>\n28.5<\/td>\n1.5<\/td>\n88.620<\/td>\n<\/tr>\n
Mean<\/td>\n2.267<\/td>\n0.316<\/td>\n0.345<\/td>\n2.003<\/td>\n29.815<\/td>\n1.5<\/td>\n90.525<\/td>\n<\/tr>\n
\u00b1SD<\/td>\n0.356<\/td>\n0.073<\/td>\n0.023<\/td>\n0.141<\/td>\n3.372<\/td>\n0.0<\/td>\n11.677<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Table 6: Pharmacokinetic of allopurinol (ug\\ml) in plasma after administration of oral 300 mg Zyloric tablet (GlaxoWelcome) to 20 healthy volunteers.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
No.,<\/strong><\/td>\nKa<\/strong><\/td>\nKa0.5t<\/strong><\/td>\nKelem.<\/strong><\/td>\nKelem.0.5t<\/strong><\/td>\nCmax<\/strong><\/td>\nTmax<\/strong><\/td>\nAUC<\/strong><\/td>\n<\/tr>\n
1<\/td>\n2.123<\/td>\n0.326<\/td>\n0.311<\/td>\n2.231<\/td>\n33.2<\/td>\n1.5<\/td>\n109.68<\/td>\n<\/tr>\n
2<\/td>\n2.134<\/td>\n0.325<\/td>\n0.339<\/td>\n2.046<\/td>\n31.2<\/td>\n1.5<\/td>\n98.86<\/td>\n<\/tr>\n
3<\/td>\n2.198<\/td>\n0.315<\/td>\n0.325<\/td>\n2.134<\/td>\n32.6<\/td>\n1.5<\/td>\n96.33<\/td>\n<\/tr>\n
4<\/td>\n2.391<\/td>\n0.289<\/td>\n0.337<\/td>\n2.058<\/td>\n29.8<\/td>\n1.5<\/td>\n89.42<\/td>\n<\/tr>\n
5<\/td>\n2.599<\/td>\n0.267<\/td>\n0.226<\/td>\n2.605<\/td>\n27.8<\/td>\n1.5<\/td>\n91.98<\/td>\n<\/tr>\n
6<\/td>\n2.662<\/td>\n0.260<\/td>\n0.325<\/td>\n2.133<\/td>\n26.3<\/td>\n1.5<\/td>\n75.31<\/td>\n<\/tr>\n
7<\/td>\n2.211<\/td>\n0.313<\/td>\n0.341<\/td>\n2.034<\/td>\n27.0<\/td>\n1.5<\/td>\n78.42<\/td>\n<\/tr>\n
8<\/td>\n2.316<\/td>\n0.299<\/td>\n0.308<\/td>\n2.252<\/td>\n29.6<\/td>\n1.5<\/td>\n88.62<\/td>\n<\/tr>\n
9<\/td>\n2.139<\/td>\n0.324<\/td>\n0.336<\/td>\n2.061<\/td>\n32.1<\/td>\n1.5<\/td>\n94.52<\/td>\n<\/tr>\n
10<\/td>\n2.071<\/td>\n0.335<\/td>\n0.292<\/td>\n2.373<\/td>\n33.9<\/td>\n1.5<\/td>\n107.9<\/td>\n<\/tr>\n
11<\/td>\n2.106<\/td>\n0.329<\/td>\n0.309<\/td>\n2.240<\/td>\n34.5<\/td>\n1.5<\/td>\n105.75<\/td>\n<\/tr>\n
12<\/td>\n2.259<\/td>\n0.307<\/td>\n0.327<\/td>\n2.120<\/td>\n33.1<\/td>\n1.5<\/td>\n102.12<\/td>\n<\/tr>\n
13<\/td>\n2.348<\/td>\n0.295<\/td>\n0.334<\/td>\n2.022<\/td>\n29.8<\/td>\n1.5<\/td>\n97.31<\/td>\n<\/tr>\n
14<\/td>\n2.539<\/td>\n0.273<\/td>\n0.313<\/td>\n2.216<\/td>\n29.7<\/td>\n1.5<\/td>\n94.86<\/td>\n<\/tr>\n
15<\/td>\n2.528<\/td>\n0.274<\/td>\n0.316<\/td>\n2.192<\/td>\n26.3<\/td>\n1.5<\/td>\n78.68<\/td>\n<\/tr>\n
16<\/td>\n2.126<\/td>\n0.326<\/td>\n0.345<\/td>\n2.008<\/td>\n30.2<\/td>\n1.5<\/td>\n86.62<\/td>\n<\/tr>\n
17<\/td>\n2.151<\/td>\n0.322<\/td>\n0.325<\/td>\n2.132<\/td>\n33.4<\/td>\n1.5<\/td>\n98.31<\/td>\n<\/tr>\n
18<\/td>\n1.850<\/td>\n0.375<\/td>\n0.342<\/td>\n2.026<\/td>\n31.5<\/td>\n1.5<\/td>\n92.41<\/td>\n<\/tr>\n
19<\/td>\n1.982<\/td>\n0.349<\/td>\n0.346<\/td>\n2.004<\/td>\n30.7<\/td>\n1.5<\/td>\n87.71<\/td>\n<\/tr>\n
20<\/td>\n2.358<\/td>\n0.294<\/td>\n0.336<\/td>\n2.063<\/td>\n28.6<\/td>\n1.5<\/td>\n81.55<\/td>\n<\/tr>\n
Mean<\/td>\n2.255<\/td>\n0.305<\/td>\n0.324<\/td>\n2.146<\/td>\n30.565<\/td>\n1.5<\/td>\n92.28<\/td>\n<\/tr>\n
\u00b1SD<\/td>\n0.212<\/td>\n0.033<\/td>\n0.020<\/td>\n0.148<\/td>\n2.507<\/td>\n0.0<\/td>\n9.752<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

The bioavailability of both formulations judged by the calculated pharmacokinetic parameters listed in Tables 5 and 6 and Figures 3 and 4.\u00a0\u00a0 Among the parameters utilized for comparison between the two formulations were the area under curve (AUC) calculated from the plasma concentration profile (Fig. 5).\u00a0\u00a0 The area was estimated by combination of linear \u2013log \u2013 linear trapezoidal method which yields more acceptable results than the linear method alone (23).<\/p>\n

The\u00a0most\u00a0concentrations of allopurinol for\u00a0each\u00a0300mg hyporic and 300mg zyloric\u00a0were\u00a029.8 and 30.6mg at\u00a0maximum\u00a0time of 1.5\u00a0hours for\u00a0both\u00a0formulation. It was not significantly differences, the results of the study were given in Tables 3 and 4.\u00a0\u00a0 Area under curve (AUC) was calculated by the linear trapezoidal rule for both Hyporic tablet and Zyloric tablet, it was found that there was no significant different (see Fig. 5).\u00a0\u00a0 The AUC0-12<\/sub> for Hyporic tablet were slightly lower than those calculated for Zyloric tablets.\u00a0 The same applies to the peak concentration Cmax\u00a0 <\/sub>(90.525ug\/ml and 92.28ug\/ml for Hyporic and Zyloric, respectively).\u00a0\u00a0\u00a0 The terminal half-life (t 1\/2<\/sub>) for both drugs are 1.5 hr., were similar time and close to the values reported by (2).<\/p>\n

Considering the pharmacokinetic parameters used in this study, one finds that the average values for the area under curve (AUC 0-12<\/sub>) corresponding to Hyporic tablet is slightly lower than the values determined for Zyloric tablet.\u00a0\u00a0 However, statistical testing showed that the differences is insignificant.<\/p>\n

The two formulations are bioequivalent for Hyporic tablet (SDI) and Zyloric tablets (GlaxoWellcome).\u00a0\u00a0 In this study, no statistically significant difference in Cmax, AUC0-12<\/sub> were found between Hyporic and Zyloric.<\/p>\n

Acknowledgements<\/strong><\/p>\n

The authors are expressing their appreciations to all those who have assisted in the research, namely the staff of Pharmacy College, the Mutah\u2019 University, and researchers at the Medical Research Centre at College of Pharmacy, Mutah\u2019 University, Jordan.<\/p>\n

Conflict of Interest<\/strong><\/p>\n

The authors do not have any conflict of interest.<\/p>\n

Funding<\/strong><\/p>\n

There is not funding source<\/p>\n

References <\/strong><\/p>\n

    \n
  1. Jill E Maddison, Stephen WPage and Timothy MDyke, 2009. Chapter 2\u00a0–\u00a0Clinical pharmacokinetics in Small Animal Clinical Pharmacology (Second Edition). 2008, Pages 27-40.<\/li>\n
  2. William N. Kelley\u00a0and\u00a0James B. Wyngaarden, Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells. J Clin Invest. 1970 Mar; 49(3): 602\u2013609.<\/li>\n
  3. Frederic Derbre, \u00a0<\/sup>Beatriz Ferrando, \u00a0<\/sup>Mari Carmen Gomez-Cabrera, \u00a0<\/sup>Fabian Sanchis-Gomar, \u00a0<\/sup>et.al., (2012). Inhibition of Xanthine Oxidase by Allopurinol Prevents Skeletal Muscle Atrophy: Role of p38 MAPKinase and E3 Ubiquitin Ligases. Journal List Plops One v.7 (10); 2012.<\/li>\n
  4. Klinenberg, J. R., Goldfinger, S. E., and Seegmiller, J. E. (1965). The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann. Intern. Med. 62, 639\u2013647.<\/li>\n
  5. Wright, D.F., Stamp, L.K., Merriman, T.R., Barclay, M.L., Duffll, S.B., and Holford, N.H. (2013). The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. European Journal of Clinical Pharmacology, 69 (7), 1411-1421.<\/li>\n
  6. Shin HS, Lee HR, Lee DC, Shim JY, Cho KH, et al. (2006) Uric acid as a prognostic\u00a0factor\u00a0for survival time: a\u00a0prospective\u00a0cohort\u00a0have a look at\u00a0of terminally\u00a0ill\u00a0cancer\u00a0patients. J Pain Symptom Manage 31: 493\u2013501.<\/li>\n
  7. Dena H. Jaffe,\u00a0Alyssa B. Klein,\u00a0Arriel Benis,\u00a0Natalia M. Flores,Hagit Gabay, etal. Incident gout and chronic Kidney Disease: healthcare utilization and survival. BMC Rheumatology<\/em>volume3, Article\u00a0number:\u00a011\u00a0(2019)<\/li>\n
  8. Roddy E, Doherty M, Roddy E, Zhang W, Doherty M, Singh J, et al.(2010). Gout. Epidemiology of gout. Arthritis Res Ther. 2010; 12:223.<\/li>\n
  9. Mikuls TR, Saag KG. New insights into gout epidemiology. Curr. Opin Rheumatol. 2006; 18:199\u2013203.<\/li>\n
  10. Suetonia C. Palmer, Allopurinol and kidney function: An update. Revue du Rhumatisme Volume 83, Issue 1,\u00a0January 2016, Pages 19-24.<\/li>\n
  11. Lisa K. Stamp,\u00a0Murray L. Barclay. How to prevent allopurinol hypersensitivity reactions? 2018. Rheumatology<\/em>, 57 (1):35\u201341.<\/li>\n
  12. Alderman, M. H., Cohen, H., Madhavan, S., and Kivlighn, S. (1999). Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34, 144\u2013150.<\/li>\n
  13. Kamilli I, Gresser U. Allopurinol and oxypurinol in human breast milk. Clin Investig. 1993; 71:161-4.<\/li>\n
  14. Freedman, D. S., Williamson, D. F., Gunter, E. W., and Byers, T. (1995). Relation of serum uric acid to mortality and ischemic heart disease. Am. J. Epidemiol. 141, 637\u2013644.<\/li>\n
  15. Fukushima, S., Thamavit, W., Kurata, Y., and Ito, N. (1986). Sodium citrate: A promoter of bladder carcinogenesis. Jpn. J. Cancer Res.77, 1\u20134. 18.<\/li>\n
  16. Qianrui Li,\u00a0Xiaodan Li,\u00a0Jing Wang,\u00a0Hongdie Liu, Joey Sum-Wing Kwong,\u00a0Hao Chen, \u00a0Ling Li,\u00a0 Sheng-Chia Chung, Anoop Shah, Yaolong Chen, \u00a0Zhenmei An, \u00a0Xin Sun, \u00a0Harry Hemingway, \u00a0Haoming Tian, \u00a0and\u00a0Sheyu Li. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019; 9(8): e026677.<\/li>\n
  17. John P. Forman, Hyon Choi,\u00a0and\u00a0Gary C. Curhan, Uric Acid and Insulin Sensitivity and Risk of Incident Hypertension. Arch Intern Med. 2009 Jan 26; 169(2): 155\u2013162.<\/li>\n
  18. Kannangra, D.R., Graham, G.G., Wright,D.F., Stocker, S.L., Portek, I., Pile, K.D., and Day, R.O. (2017). Individualizing the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology, 83(9), 2015-2026.<\/li>\n
  19. 19. XiaLiu, Xiao-JiaNi, \u00a0De-WeiShang , MingZhang, Jin-QingHu, ChangQiua<\/sup>Fu-TianLuo, Yu-GuanWen. Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 2013, 941:10-16.<\/li>\n
  20. Helmy SA, El-Bedaiwy HM. Pharmacokinetics and comparative bioavailability of allopurinol formulations in healthy subjects.\u00a0Clin Pharmacol Drug Dev<\/em>. 2014; 3(5):353\u2013357.<\/li>\n
  21. Rathod DM, Patel KR, Mistri HN, Jangid AG, Shrivastav PS, Sanyal M. Simultaneous analysis of allopurinol and oxypurinol using a validated liquid chromatography-tandem mass spectrometry method in human plasma.\u00a0J Pharm Anal<\/em>. 2017; 7(1):56\u201362.<\/li>\n
  22. Guerra\u00a0P; Frias\u00a0J; Ruiz\u00a0B; Soto\u00a0A; Carcas\u00a0A; Govantes\u00a0C; Montuenga\u00a0C; Fern\u00e1ndez\u00a0A, Clinical Trials Unit, School of Medicine, Universidad Aut\u00f3noma Madrid, Spain. Bioequivalence of allopurinol and oxipurinol in two tablet formulations Pedro. J. Clin. Pharm. Ther. \u00a02001; 26 (2):113-9.<\/li>\n
  23. 23. Wojciech Jawie\u0144. Searching for an optimal AUC estimation method: a never-ending task? J. Pharmacokinet Pharmacodyn. 2014; 41(6): 655\u2013673.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction Description The chemical structure of allopurinol is 1, 5-dihydro-4H-pyrazolo […]<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[77],"tags":[],"class_list":["post-33985","post","type-post","status-publish","format-standard","hentry","category-vol13no2"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/33985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=33985"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/33985\/revisions"}],"predecessor-version":[{"id":34392,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/33985\/revisions\/34392"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=33985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=33985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=33985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}